If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Director/PDMR Shareholding

7 Jun 2023 07:00

RNS Number : 8702B
NetScientific PLC
07 June 2023
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Director/PDMR Shareholding

 

 

NetScientific Plc (AIM: NSCI), the investment and commercialisation group with an international portfolio of innovative life science, sustainability and industrial technology companies, announces that on 6 June 2023, Dr. Jonathan Robinson (Interim Non-Executive Chair and a Director of the Company) purchased shares in NetScientific Plc into his Self Invested Personal Pension.

 

Following the purchase, Dr. Jonathan Robinson now holds 174,253 shares, representing 0.74 Per cent. of the Company's issued share capital.

 

The following notification, made pursuant to Article 19(3) of the Market Abuse Regulation, provides further details.

 

NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR PERSONS CLOSELY ASSOCIATED WITH THEM

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Jonathan Robinson

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of NSCI shares into SIPP

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.5998

25,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

6 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

# # #

 

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel 

+44 (0)20 7220 1666

Belvedere Communications

John West / Llew Angus

 

+44 (0)20 3008 6867

 

About NetScientific

NetScientific plc (AIM: NSCI) is an investment and commercialisation group with an international portfolio of innovative life science, sustainability and technology companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSSFAMEDSEFM
Date   Source Headline
30th Nov 20201:56 pmRNSEMV Capital leads a £1.28m investment in SageTech
19th Nov 20207:00 amRNSProAxsis appoints DiaPharma as distributor
11th Nov 20202:10 pmRNSPDS updates on Versamune based COVID-19 vaccine
10th Nov 202012:47 pmRNSPDS Biotech Initiates VERSATILE-002 Phase 2 Trial
27th Oct 20209:46 amRNSPDS Announces Initiation of PDS0101 Phase 2 Trial
16th Oct 20207:00 amRNSNetScientific acquires 100% of portfolio company
30th Sep 20209:08 amRNSDirector/PDMR Shareholding
30th Sep 20209:07 amRNSHolding(s) in Company
30th Sep 20208:58 amRNSHolding(s) in Company
25th Sep 202012:37 pmRNSGrant of Options to Director
24th Sep 20207:00 amRNSInterim Results
2nd Sep 20207:00 amRNSHolding(s) in Company
2nd Sep 20207:00 amRNSHolding(s) in Company
24th Aug 202011:28 amRNSResult of General Meeting
21st Aug 20201:23 pmRNSHolding(s) in Company
21st Aug 202011:47 amRNSIssue of Equity
14th Aug 202010:48 amRNSPDS Announces Closing of $19m Offering
12th Aug 202012:28 pmRNSSofant secures £2.3m funding led by EMV Capital
12th Aug 20207:00 amRNSPDS Announces Pricing of $16.5m Common Stock Offer
11th Aug 202012:27 pmRNSPDS Announces Proposed Offering of Common Stock
7th Aug 20209:32 amRNSPosting of shareholder circular
6th Aug 20202:00 pmRNSHolding(s) in Company
5th Aug 202010:32 amRNSResult of Placing
5th Aug 20208:30 amRNSProposed acquisition and placing
4th Aug 202011:05 amRNSSecond Price Monitoring Extn
4th Aug 202011:00 amRNSPrice Monitoring Extension
27th Jul 20203:06 pmRNSPDS Announces Preclinical Data for PDS0203
14th Jul 20204:20 pmRNSPDS collaborator awarded grant for Versamune
29th Jun 20207:00 amRNSG–Tech Medical completes $6.7m Series A financing
25th Jun 20204:41 pmRNSSecond Price Monitoring Extn
25th Jun 20204:35 pmRNSPrice Monitoring Extension
24th Jun 20205:58 pmRNSHolding(s) in Company
24th Jun 20205:54 pmRNSHolding(s) in Company
24th Jun 20204:09 pmRNSResult of AGM
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
18th Jun 202011:05 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
18th Jun 20209:05 amRNSSecond Price Monitoring Extn
18th Jun 20209:00 amRNSPrice Monitoring Extension
18th Jun 20207:00 amRNSPDS & Farmacore Announce Co-Development-PDS0204
15th Jun 20202:41 pmRNSPDS Announces Initiation of Phase 2 Trial PDS0101
8th Jun 20204:42 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
5th Jun 20209:14 amRNSPDS Announces Trial of its Lead Product, PDS0101
1st Jun 20207:00 amRNSNotice of AGM
13th May 20202:46 pmRNSPDS Reports Results for Q1 2020 & Business Update
1st May 202011:33 amRNSConfirmation of Board Changes
30th Apr 202012:06 pmRNSPDS expands CRADA with National Cancer Institute
27th Apr 20207:00 amRNSPreliminary Results for the year ended 31 Dec 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.